Simon Willy Jules 4

What Happened

• Simon Willy Jules, a director of OKYO Pharma Ltd (OKYO), was granted a derivative award covering 6,500 shares on 2026-06-08. The award is reported at a price of $1.85 per share, for a notional value of $12,025. This was an award/grant (transaction code A), not an open-market purchase or sale — typically a form of compensation rather than a direct bullish or bearish trade.

Key Details

• Transaction date: 2026-06-08; Filing date: 2026-06-10 (filed timely).
• Award amount: 6,500 shares; price used: $1.85 per share; total reported value: $12,025.
• Security type: Derivative award (grant of equity-based award — e.g., options or RSUs); transaction code A.
• Vesting: 25% per year over four years, beginning on the first anniversary of the grant date.
• Shares owned after transaction: Not specified in the filing.
• No 10b5-1 plan, tax-withholding, exercise, or immediate sale was reported in this Form 4.

Context

• This is a standard compensation grant to an insider. Because it’s an award (derivative) with a multi-year vesting schedule, it represents future potential equity rather than an immediate ownership change or sale. Retail investors typically view grants as routine corporate compensation; they do not necessarily indicate short-term insider sentiment.